脑胶质瘤患者MGMT启动子甲基化和IDH1突变与临床预后相关

Correlations of MGMT promoter methylation and IDH1 mutations with the clinical prognosis of malignant glioma patients

目的本研究回顾性分析MGMT、IDH1在脑胶质瘤患者中的突变及表达状况,探讨二者共表达与临床预后之间的关系。方法将放射治疗科2017年10月至2019年10月收治的25例脑胶质瘤术后患者纳入本研究;采用Kaplan-Meier法分析生存率;Log-rank法进行单因素分析。结果MGMT启动子甲基化患者(χ^(2)=4.22,P<0.05)较非甲基化者的总生存期(OS)明显延长,MGMT甲基化患者较非甲基化患者的疾病无进展生存时间(PFS)、IDH1阳性患者的OS、PFS较阴性患者无明显延长。MGMT甲基化联合IDH1突变患者较MGMT非甲基化联合IDH1无突变患者生存期明显延长(P<0.05)。结论脑胶质瘤术后患者的MGMT甲基化及IDH1基因水平与OS、PFS显著相关,是影响患者临床预后的重要因素。

Objective To analyze retrospectively the IDH1 mutation and MGMT promoter methylation of malignant glioma patients and to identify potential relation to clinical situation.Methods Twenty-five patients with glioma who were received treatment from October 2017 to October 2019 were selected;the survival rate was calculated by Kaplan-Meier method and analyzed by Log-Rank test.Results Univariate analysis showed that negative status of MGMT gene promoter methylation(χ^(2)=4.22,P<0.05)was an important factor affecting the survival rates of patients,and patients with both negative status of MGMT gene promoter methylation and mutation of IDH1 had a significantly prolonged survival(P<0.05).Conclusions IDH mutation and MGMT promoter methylation status are significantly related to the prognosis of malignant glioma patients.